平阳霉素注射剂联合放疗治疗头面部皮肤癌的临床研究
|
摘要
目的观察平阳霉素注射剂联合放疗治疗头面部皮肤癌的临床疗效及安全性。方法将90例头面部皮肤癌患者随机分为对照组43例和试验组47例。对照组予以放射治疗,每次2 Gy,每周5次,总照射剂量68 Gy;试验组在对照组治疗的基础上,于首次化疗结束后给予平阳霉素每次4～8 mg,肌内注射,1次未痊愈者间隔7～10 d重复注射,总剂量不超过70 mg。比较2组患者的临床疗效和药物不良反应的发生情况。结果治疗后,试验组和对照组的总缓解率分别为59. 57%(28例/47例)和37. 21%(16例/43例),差异有统计学意义(P <0. 05)。2组患者的药物不良反应均以口腔炎、脱发、恶心呕吐和白细胞减少为主,且各药物不良反应的发生率比较,差异均无统计学意义(均P> 0. 05)。结论平阳霉素注射剂联合放疗治疗头面部皮肤癌的临床疗效显著,且不增加药物不良反应的发生率。
Objective To observe the clinical efficacy and safety of pingyangmycin injection combined with radiotherapy in the treatment of skin cancer of head and face. Methods A total of 90 patients with skin cancer of head and face were randomly divided into control group( n = 43 cases) and treatment group( n = 47 cases). Control group was given radiotherapy treatment with 2 Gy per time,5 times a weeks,and the total dose was 68 Gy. Treatment group was given pingyangmycin 4-8 mg,intramuscular injection. Repeated injections were given at intervals of 7 to 10 days for those who did not recover,with a total dose not exceeding 70 mg. The clinical efficacy and adverse drug reactions were compared between two groups. Results After treatment,the total remission rates of treatment and control groups were 59. 57%( 28 cases/47 cases) and37. 21%( 16 cases/43 cases) with significant difference( P < 0. 05).The adverse drug reactions of two groups were stomatitis,alopecia,nausea and vomiting,and leukopenia. There were no significant differences in the incidences of adverse drug reactions between two groups( all P > 0. 05).Conclusion Pingyangmycin injection combined with radiotherapy has a definitive clinical efficacy in the treatment of skin cancer of head and face,without increasing the incidences of adverse drug reactions.
Objective To observe the clinical efficacy and safety of pingyangmycin injection combined with radiotherapy in the treatment of skin cancer of head and face. Methods A total of 90 patients with skin cancer of head and face were randomly divided into control group( n = 43 cases) and treatment group( n = 47 cases). Control group was given radiotherapy treatment with 2 Gy per time,5 times a weeks,and the total dose was 68 Gy. Treatment group was given pingyangmycin 4-8 mg,intramuscular injection. Repeated injections were given at intervals of 7 to 10 days for those who did not recover,with a total dose not exceeding 70 mg. The clinical efficacy and adverse drug reactions were compared between two groups. Results After treatment,the total remission rates of treatment and control groups were 59. 57%( 28 cases/47 cases) and37. 21%( 16 cases/43 cases) with significant difference( P < 0. 05).The adverse drug reactions of two groups were stomatitis,alopecia,nausea and vomiting,and leukopenia. There were no significant differences in the incidences of adverse drug reactions between two groups( all P > 0. 05).Conclusion Pingyangmycin injection combined with radiotherapy has a definitive clinical efficacy in the treatment of skin cancer of head and face,without increasing the incidences of adverse drug reactions.
引文
[1] MIERZWA M L. Radiotherapy for Skin cancers of the face,head,and neck[J]. Facial Plast Surg Clin North Am,2019,27(1):131-138.
[2] PENG L X,ZHAO P,ZHAO H S,et al. Phosphoinositide 3-kinase/Akt pathway is involved in pingyangmycin? Induced growth inhibition,apoptosis and reduction of invasive potential in EOMA mouse hemangioendothelioma cells[J]. Mol Med Rep,2015,12(6):8275-8281.
[3]孙明,王蔚文.临床疾病诊断与疗效判断标准[M].北京:科学技术文献出版社,2010:1278-1280.
[4]杨学宁,吴一龙.实体瘤治疗疗效评价标准—RECIST[J].循证医学,2004,4(2):85-90.
[5] LUCERO O M,ECHAIZ C F,JAFARIAN F,et al. Keratinocyte carcinomas arising near arteriovenous fistulas:Case series and safety considerations for dermatologic surgery:A report of the international transplant skin cancer collaborative[J]. JAAD Case Rep,2018,5(1):7-11.
[6]王月,杨希川.皮肤鳞状细胞癌的研究进展[J].实用皮肤病学杂志,2016,9(1):38-40.
[7]王松林,潘金华,龙道国.放疗联合5-氟尿嘧啶局部化疗对头面部及四肢皮肤癌的临床疗效观察[J].现代医学,2018,46(5):483-486.
[8]冯嘉铁,张连仲,董兵.平阳霉素联合放疗治疗晚期皮肤癌的疗效观察[J].河北医学,2017,23(3):427-430.
[2] PENG L X,ZHAO P,ZHAO H S,et al. Phosphoinositide 3-kinase/Akt pathway is involved in pingyangmycin? Induced growth inhibition,apoptosis and reduction of invasive potential in EOMA mouse hemangioendothelioma cells[J]. Mol Med Rep,2015,12(6):8275-8281.
[3]孙明,王蔚文.临床疾病诊断与疗效判断标准[M].北京:科学技术文献出版社,2010:1278-1280.
[4]杨学宁,吴一龙.实体瘤治疗疗效评价标准—RECIST[J].循证医学,2004,4(2):85-90.
[5] LUCERO O M,ECHAIZ C F,JAFARIAN F,et al. Keratinocyte carcinomas arising near arteriovenous fistulas:Case series and safety considerations for dermatologic surgery:A report of the international transplant skin cancer collaborative[J]. JAAD Case Rep,2018,5(1):7-11.
[6]王月,杨希川.皮肤鳞状细胞癌的研究进展[J].实用皮肤病学杂志,2016,9(1):38-40.
[7]王松林,潘金华,龙道国.放疗联合5-氟尿嘧啶局部化疗对头面部及四肢皮肤癌的临床疗效观察[J].现代医学,2018,46(5):483-486.
[8]冯嘉铁,张连仲,董兵.平阳霉素联合放疗治疗晚期皮肤癌的疗效观察[J].河北医学,2017,23(3):427-430.